India Ratings and Research has upgraded Glenmark Pharmaceuticals Ltd’s (GPL) long-term bank loans to ‘IND AA+’ from ‘IND AA’, affirming a Stable Outlook. The agency also affirmed the short-term bank loans at ‘IND A1+’. This upgrade reflects improved financial visibility at its subsidiary, Ichnos Glenmark Innovation, and GPL’s strong credit profile, including enhanced liquidity and operating profitability expectations.
India Ratings Elevates Glenmark’s Credit Profile
Glenmark Pharmaceuticals Limited (GPL) has received a significant credit rating upgrade from India Ratings and Research (Ind-Ra). The agency has upgraded GPL’s long-term bank loans to ‘IND AA+’/Stable from ‘IND AA’, while affirming the short-term bank loans at ‘IND A1+’. This positive development highlights the strengthening creditworthiness and financial outlook of the company.
Key Drivers for the Upgrade
The rating upgrade is primarily driven by the expectation of improved financial visibility at Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of GPL. This stems from the ISB 2001 licensing agreement finalized in July 2025, which is set to significantly reduce IGI’s reliance on GPL for capital. Ind-Ra anticipates that GPL will likely see enhanced profitability and annual cash flows, supported by around USD70 million in FY27-FY28. The deal also provides substantial upfront proceeds which bolster GPL’s balance sheet and liquidity.
Strengthened Financials and Business Outlook
Ind-Ra also points to a projected improvement in GPL’s operating profitability over FY27-FY30, its diversified business profile, and comfortable credit metrics. The company’s robust liquidity position and financial flexibility are key strengths. Despite a challenging environment, GPL’s ability to maintain revenue and profitability growth, coupled with prudent utilization of proceeds from the licensing deal, are considered key monitorables.
Details of Instruments
| Instrument Type | Regulator of Instrument | Date of Issuance | Coupon Rate | Maturity Date | Size of Issue (INR million) | Rating Assigned with Outlook/Watch | Rating Action |
| Bank loan facilities | RBI | – | – | – | 18,500 | IND AA+/Stable/IND A1+ | Long-term rating upgraded; short-term rating affirmed |
| Bank loan facilities | RBI | – | – | – | 23,500 | IND AA+/Stable/IND A1+ | Assigned |
Key Strengths Identified
- The ISB 2001 deal significantly strengthens GPL’s balance sheet and de-risks its innovation spend.
- GPL maintains a strong credit profile with expected negative net adjusted leverage.
- A well-diversified business profile and strong revenue growth are anticipated.
- A strong recovery in the US business is likely over FY27-FY30.
- Robust secondary sales growth in the Indian business, despite channel realignments.
Regulatory Considerations
While the outlook is positive, Ind-Ra notes potential regulatory overhangs related to price controls in India and ongoing USFDA scrutiny of manufacturing facilities. The company’s exposure to regulated markets means it remains susceptible to adverse regulatory actions. The resolution of pending USFDA issues and price-control measures are key factors to watch.
Source: BSE
